MedPath

MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Registration Number
NCT02468791
Lead Sponsor
Mabion SA
Brief Summary

The purpose of this study is to evaluate biosimilarity between test product MabionCD20® and the reference product - MabThera® (rituximab) and to demonstrate comparative safety and tolerability of a single course of treatment of MabionCD20® and MabThera® in patients with moderate to severe active rheumatoid arthritis.

Detailed Description

Subjects who meet the criteria for participation in this study receive 2 intravenous infusions of MabionCD20® or MabThera® with two weeks interval in combination with methotrexate and folic acid. After the treatment period, patients are followed for 24 weeks, in order to continue checking safety. Therefore, the total study lasts 48 weeks. There is a possibility to repeat treatment after 6 months of the first infusions if subject meets the retreatment criteria.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
709
Inclusion Criteria
  • Patients with active rheumatoid arthritis with disease duration minimum 6 months prior to screening visit
  • Patients who are naive to tumor necrosis factor (TNF) antagonists or any other monoclonal antibody therapies
  • Patients who have had an inadequate response to an adequate regimen of methotrexate
Exclusion Criteria
  • History of current rheumatic autoimmune disease other than RA and current inflammatory joint disease other than RA
  • Contraindications according to the MabThera SmPC and every serious coexisting diseases which, in the Investigator's opinion, would preclude subject participation
  • Positive tests for HIV, hepatitis B surface antigen (HBsAg) Anti-HBc antibody, hepatitis C antibody
  • Prior treatment with rituximab, other anti-CD20 mAb, anti-TNF-alpha drug or any other monoclonal antibodies
  • Pregnancy or lactation or women planning to get pregnant during the course of the study and/or within 12 months post last study drug infusion
  • Allergic reaction or intolerance to rituximab, MabionCD20 or any of their components
  • Severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or previous treatment of any lymphocyte-depleting therapies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MabThera®RituximabA course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
MabionCD20®RituximabA course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
Primary Outcome Measures
NameTimeMethod
Percentage of patients in each treatment group achieving the primary efficacy endpoint of a ≥ 20% improvement on the American College of Rheumatology score (ACR20) at Week 24.24 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (51)

NSZOZ Unica CR

🇵🇱

Dopiewo, Poland

IRMED

🇵🇱

Warszawa, Poland

University Clinical Centre Tuzla

🇧🇦

Tuzla, Bosnia and Herzegovina

Centrum Miriada

🇵🇱

Białystok, Poland

Wojewódzki Szpital Zespolony

🇵🇱

Elbląg, Poland

Małopolskie Centrum Medyczne S.C.

🇵🇱

Kraków, Poland

Szpital Uniwersytecki, Oddział Kliniczny Kliniki Chorób Wewnętrznych

🇵🇱

Kraków, Poland

Szpital Specjalistyczny im. J. Dietla

🇵🇱

Kraków, Poland

Tbilisi Heart and Vascular Clinic

🇬🇪

Tbilisi, Georgia

REUMED

🇵🇱

Lublin, Poland

National Medical University, Chair of Internal Medicine based on Ivano-Frankivsk Central Clinical City Hospital

🇺🇦

Ivano-Frankivsk, Ukraine

Clinical Centre Banja Luka Location Paprikovac

🇧🇦

Banja Luka, Bosnia and Herzegovina

Clinical Centre University of Sarajevo

🇧🇦

Sarajevo, Bosnia and Herzegovina

Cardio-Reanimation Center Ltd

🇬🇪

Tbilisi, Georgia

Diagnostic Service ltd

🇬🇪

Tbilisi, Georgia

Medulla-Chemotherapy and Immunotherapy Clinic

🇬🇪

Tbilisi, Georgia

Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy

🇵🇱

Bydgoszcz, Poland

Ośrodek Badań Klinicznych

🇵🇱

Lublin, Poland

NZOZ Lecznica MAK-MED. S.C.

🇵🇱

Nadarzyn, Poland

Clinical Center Kragujevac

🇷🇸

Kragujevac, Serbia

MediClub Georgia

🇬🇪

Tbilisi, Georgia

Medicore Ltd

🇬🇪

Tbilisi, Georgia

Centrum Położnicze św Łukasza Sp.z.o.o

🇵🇱

Częstochowa, Poland

AL Klinika

🇵🇱

Poznań, Poland

Medica Pro Familia Sp. z o.o. S.K.A

🇵🇱

Warsaw, Poland

Linea Corporis Spółka z Ograniczoną Odpowiedzialnością

🇵🇱

Warszawa, Poland

State Institute "L T Malaya Institute of Therapy of NAMS of Ukraine"

🇺🇦

Kharkiv, Ukraine

Uzhgorod Clinical Hospital of the Lviv Railways, Department of Therapy

🇺🇦

Uzhgorod, Ukraine

NZOZ Poradnia Leczenia Osteoporozy i Chorób Narządu Ruchu

🇵🇱

Stalowa Wola, Poland

Zespół Opieki Zdrowotnej w Suchej Beskidzkiej

🇵🇱

Sucha Beskidzka, Poland

Instytut Reumatologii

🇵🇱

Warszawa, Poland

Institute for Rheumatology - Belgrade

🇷🇸

Belgrade, Serbia

Zaporizhzhia Medical Academy of Postgraduate Education of Ministry of Health of Ukraine

🇺🇦

Zaporizhzhia, Ukraine

Communal Medical Institution "City Clinical Hospital no 3"

🇺🇦

Chernivtsi, Ukraine

Administration of Medical Service and Rehabilitation of "ARTEM" State Holding Company

🇺🇦

Kyiv, Ukraine

Clinical City Hospital no 7

🇺🇦

Zaporizhzhia, Ukraine

Regional Hospital Veterans of War

🇺🇦

Kharkiv, Ukraine

University Clinical Hospital Mostar

🇧🇦

Mostar, Bosnia and Herzegovina

General Hospital "Dr. Abdulah Nakas"

🇧🇦

Sarajevo, Bosnia and Herzegovina

Carabs Medline Ltd

🇬🇪

Tbilisi, Georgia

SOLUMED

🇵🇱

Poznań, Poland

Centrum Medyczne Nowa Sól

🇵🇱

Nowa Sól, Poland

Śląski Szpital Reumatologiczo-Rehabilitacyjny im. Generała Jerzego Ziętka

🇵🇱

Ustroń, Poland

KO-MED Centra Kliniczne

🇵🇱

Zamość, Poland

Centrum Medyczne AMED

🇵🇱

Warszawa, Poland

Institute for treatment and rehabilitation "Niska Banja"

🇷🇸

Niska Banja, Serbia

Department of Cardiology and Functional Diagnostics, Kharkiv Medical Academy of Postgraduated Education

🇺🇦

Kharkiv,, Ukraine

Clinical center of Vojvodina, Clinic for medical rehabilitation

🇷🇸

Novi Sad, Serbia

Kharkiv City Clinical Hospital no 27

🇺🇦

Kharkiv, Ukraine

National Scientific Center "M.D. STRAZHESKO INSTITUTE OF CARDIOLOGY, MAS OF UKRAINE"

🇺🇦

Kyiv, Ukraine

Chair of Internal Medicine no 2 of Ternopil State Medical University

🇺🇦

Ternopil, Ukraine

© Copyright 2025. All Rights Reserved by MedPath